LatiniS, PedataF. Adenosine in the central nervous system: Release mechanisms and Extracellular Concentrations. J Neurochem. 2001; 79:1–23.
2.
HoilandRL, BainAR, RiegerMG, et al.Hypoxemia, oxygen content, and the regulation of cerebral blood flow. Am J Physiol Regul Integr Comp Physiol. 2016; 310:R398–R413.
3.
ChenJ-F, SonsallaP, PedataF, et al.Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multi-faced actions and “fine tuning” modulation. Prog Neurobiol. 2007; 83:10–331.
4.
PedataF, DettoriI, CoppiE, et al.Purinergic signalling in brain ischemia. Neuropharmacology. 2016; 104:105–130.
5.
HatfieldSM, SitkovskyM. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol. 2016; 29:90–96.
6.
BowserJL, LeeJW, YuanX, et al.The hypoxia-adenosine link during inflammation. J Appl Physiol. (1985), 2017; 123:1303–1320.
7.
KiersD, WielockxB, PetersE, et al.Hypoxia dampens inflammation in vivo via enhanced adenosine release and adenosine 2B receptor stimulation. EBioMedicine. 2018; 33:144–156.
8.
EalesKL, HollinsheadKER, TennantDA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016; 5:e190.
9.
HatfieldSM, KjaergaardJ, LukashevD, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. SciTranslMed. 2015; 7:277.
10.
VijayanD, YoungA, MicheleWL, et al.Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer, 2017; 17:709–724.
